Gilead Sciences (Gilead Sciences) Total Inventories

: $1,787 Mil (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

Gilead Sciences's total inventories for the quarter that ended in Dec. 2023 was $1,787 Mil. Gilead Sciences's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $1,725 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Gilead Sciences's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-22.18.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Gilead Sciences's Days Inventory for the three months ended in Dec. 2023 was 75.31.

Inventory Turnover measures how fast the company turns over its inventory within a year. Gilead Sciences's Inventory Turnover for the quarter that ended in Dec. 2023 was 1.21.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Gilead Sciences's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.24.

Gilead Sciences Total Inventories Historical Data

The historical data trend for Gilead Sciences's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

922.00

1,683.00

1,618.00

1,507.00

1,787.00

Gilead Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories																1,507.00	1,576.00	1,633.00	1,663.00	1,787.00

Gilead Sciences Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Gilead Sciences (NAS:GILD) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Gilead Sciences's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(7264	+	0.75 * 4660	+	0.5 * 1787	-	39376
-	0	-	-84)	/	1246.04
=	-22.18

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Gilead Sciences's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	1725	/	2090	*	365 / 4
	=	75.31

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Gilead Sciences's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	2090	/	1725
	=	1.21

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Gilead Sciences's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	1725	/	7114
	=	0.24

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Gilead Sciences Total Inventories Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (Gilead Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Executives

Andrew D Dickinson	officer: EVP, Chief Financial Officer	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Johanna Mercier	officer: Chief Commercial Officer	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey	officer: Chief Medical Officer	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson	officer: SVP, Controllership	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong	officer: SVP, Controller & CAO	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman	officer: EVP, Corporate Affairs & GC	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher	officer: EVP, Gen Counsel & Corp Sec	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Jeffrey Bluestone	director	C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Anthony Welters	director
Javier Rodriguez	director	601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan	director	2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson	director	C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold	director	C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley	director	UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711